Pediatric blood & cancerAdolescentChildPreschoolFemaleHumans
A Phase I Trial of Nab-Paclitaxel in Combination With Gemcitabine for Relapsed/Refractory Pediatric Solid Tumors.
Jonathan Metts, Kevin Ginn, Zhulin He, Rohali Keesari, Jane C Cook, Stacy Senn, Melissa Schink, Samer Sansil, Hong Yin, Thomas Cash
Published: 202610.1002/pbc.32102
Abstract
BACKGROUND: The single-agent pediatric maximum tolerated dose (MTD) of nab-paclitaxel is significantly higher than adult dosing. We conducted a Phase I trial to establish the MTD/recommended Phase 2 dose (RP2D) of nab-paclitaxel with gemcitabine in c…
Preview only. Read the full abstract at the source